Neurocentria, Inc.
Clinical trials sponsored by Neurocentria, Inc., explained in plain language.
-
ADHD combo drug trial stops early – only 2 teens enrolled
Symptom relief TerminatedThis phase 2 trial tested a combination of two drugs, NRCT-101SR and NRCT-202XR, for teens with ADHD. The goal was to see if the combo could ease symptoms and reduce side effects better than one drug alone. However, the study was terminated early and only enrolled 2 participants,…
Phase: PHASE2 • Sponsor: Neurocentria, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
ADHD drug trial for teens halted early – what we know
Symptom relief TerminatedThis study tested a new medicine called NRCT-101SR for teenagers aged 13 to 17 with ADHD. The goal was to see if it safely reduces ADHD symptoms compared to a placebo. The trial was stopped early, so results are limited. It involved 95 participants and used standard ADHD rating s…
Phase: PHASE2, PHASE3 • Sponsor: Neurocentria, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC